Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
First patient treated in Takeda’s phase 3 trial for alpha-1 antitrypsin deficiency
Arrowhead Pharmaceuticals announced that the first patient has been treated in Takeda Pharmaceuticals’ phase 3 clinical trial of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease.
Adenovirus re-emerges as likely culprit in 2022 outbreak of acute hepatitis in children
A 2022 outbreak of unexplained acute severe hepatitis in children has been linked to a strain of adeno-associated virus 2, supporting the theory that disease pathogenesis results from viral coinfection, according to data reported in Nature.
Log in or Sign up for Free to view tailored content for your specialty!
Time-restrictive eating no more effective than daily calorie restriction in NAFLD
Compared with daily calorie restriction, time-restricted eating did not achieve additional benefits for reducing intrahepatic triglyceride content or body fat among patients with nonalcoholic fatty liver disease and obesity.
No difference between semaglutide, placebo in fibrosis improvement in patients with NASH
Although semaglutide did not “significantly improve” fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, notable improvements were reported in cardiometabolic parameters and markers of liver fat and injury.
Higher poverty linked to lower rates for surgical resection in colorectal liver metastasis
Patients in U.S. counties with higher poverty were less likely to undergo liver metastasectomy for colorectal liver metastasis, suggesting that access to surgery for complex gastrointestinal cancers may be affected by social determinants.
FDA limit on acetaminophen dosage linked to fewer hospitalizations, cases of liver failure
A 2011 FDA mandate, which limited acetaminophen dosage to 325 mg/tablet in prescription acetaminophen and opioid products, correlated with a decrease in yearly hospitalizations and cases of acute liver failure related to toxicity.
High mortality rates prove lean patients with NAFLD should ‘be taken seriously’
Lean patients with nonalcoholic fatty liver disease had significantly higher mortality than non-lean patients, despite having lower rates of cirrhosis and diabetes, according to research in Alimentary Pharmacology & Therapeutics.
HCV elimination represents ‘win-win-win’ for patients, public health, cost savings
Every year nearly 3 million patients are diagnosed with hepatitis B and C infections, ultimately leading to 1.1 million deaths worldwide, WHO reported.
Controlling HCV: ‘The time for political action is here’
In 2015, WHO initiated a campaign to eliminate hepatitis B and C worldwide.
90-day fills for chronic hepatitis B treatments increased patient adherence
Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read